Bristol-Myers Squibb Services Unlimited Company

Address
Plaza 254, Blanchardstown Corporate Park 2

Sponsor Overview

assignment
92
sponsored trials
science
76
molecules
location_city
1000
research centres
public
22
countries
person_search
2042
investigators

Specializations

Oncology

The sponsor’s oncology portfolio spans non-small cell lung cancer, melanoma, urothelial cancer, breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, gastric and gastroesophageal cancers, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, bladder cancer, and myelofibrosis. It also includes studies in acute myeloid leukemia, myelodysplastic syndrome, primary central nervous system lymphoma, and other advanced solid tumors.

  • Immuno-oncology
  • Targeted therapy
  • Metastatic cancer
  • Hematologic malignancies
  • Perioperative and first-line cancer treatment

Research activity includes treatment of EGFR-mutated and KRAS G12C-mutant disease, as well as platinum-resistant and unresectable cancer settings.

Autoimmune and inflammatory disease

Clinical research in immune-mediated disease centers on systemic lupus erythematosus, cutaneous lupus erythematosus, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis, idiopathic inflammatory myopathy, ulcerative colitis, and atopic dermatitis.

  • Systemic lupus erythematosus
  • Psoriatic arthritis
  • Psoriasis
  • Inflammatory bowel disease
  • Connective tissue disease

Additional work extends to juvenile psoriatic arthritis and pediatric immune-mediated conditions.

Neurology and psychiatry

The sponsor funds trials in Alzheimer’s disease, including early and mild to moderate stages, with associated agitation and psychosis. Its neuroscience portfolio also includes bipolar I disorder, mania, schizophrenia, and relapsing remitting multiple sclerosis.

  • Alzheimer’s disease
  • Bipolar I disorder
  • Schizophrenia
  • Multiple sclerosis
  • Neuropsychiatric symptoms

Research also addresses primary central nervous system lymphoma within the broader neuro-oncology landscape.

Pulmonary and cardiovascular disease

Respiratory and cardiometabolic studies include idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and heart failure with preserved ejection fraction. Cardiovascular research also covers symptomatic obstructive hypertrophic cardiomyopathy.

  • Interstitial lung disease
  • Pulmonary fibrosis
  • Heart failure
  • Hypertrophic cardiomyopathy

These programs reflect interest in chronic cardiopulmonary disorders with significant unmet treatment need.

Hematology, transplantation, and rare disease

Additional clinical work includes sickle cell disease, renal transplantation, and adolescent renal allograft care, alongside studies in myelofibrosis and other hematologic disorders. The portfolio also extends to urothelial carcinoma and solid malignancies with high-risk or refractory features.

  • Sickle cell disease
  • Renal transplantation
  • Myelofibrosis
  • Urothelial carcinoma

Research activity in these areas spans both chronic disease management and oncology-linked rare conditions.

Sponsored Trials

Trial Name Country Status
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to Severe Plaque PsoriasisFrance FranceGermany GermanyPoland PolandRomania RomaniaSpain SpainRecruiting
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque PsoriasisBelgium BelgiumGermany GermanyHungary HungaryItaly ItalyPoland PolandRomania RomaniaSpain SpainRecruiting
A Phase 1/1b First-in-Human Study to Evaluate the Safety and Pharmacokinetics of BMS-986506 in Patients with Advanced Clear Cell Renal Cell CarcinomaFrance FranceSpain SpainRecruiting
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial CarcinomaAustria AustriaBelgium BelgiumDenmark DenmarkFrance FranceGermany GermanyGreece GreeceIreland IrelandItaly ItalyPoland PolandRomania RomaniaSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple SclerosisItaly ItalyPoland PolandPortugal PortugalRomania RomaniaSpain SpainRecruiting
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial CancerCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceItaly ItalyNorway NorwayPoland PolandRomania RomaniaSpain SpainThe Netherlands The NetherlandsNot Recruiting
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 76K)Austria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyGreece GreeceItaly ItalyNorway NorwayPoland PolandRomania RomaniaSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (CheckMate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 77T)Belgium BelgiumCzechia CzechiaFrance FranceGermany GermanyItaly ItalyPoland PolandRomania RomaniaSpain SpainThe Netherlands The NetherlandsNot Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Idiopathic Pulmonary FibrosisAustria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyGreece GreeceHungary HungaryIreland IrelandItaly ItalyPoland PolandPortugal PortugalSpain SpainThe Netherlands The NetherlandsNot Yet Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary FibrosisAustria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyGreece GreeceHungary HungaryIreland IrelandItaly ItalyPoland PolandPortugal PortugalSpain SpainThe Netherlands The NetherlandsNot Yet Recruiting
1–10 of 92
1 / 10

Data & Insights

science
Molecule Portfolio
Compounds under investigation
10
Exclusive Molecules
out of 76 total (13% not shared with other sponsors)

This sponsor works with 76 molecules, of which 10 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
55%
Return partnership rate
551 of 1000 sites collaborated multiple times

This sponsor has worked with 1000 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms51 trials
    853 other sponsors
  • 2.
    Immune System Diseases14 trials
    322 other sponsors
  • 3.
    Mental Disorders13 trials
    150 other sponsors
  • 4.
    Nervous System Diseases6 trials
    449 other sponsors
  • 5.
    Respiratory Tract Diseases3 trials
    277 other sponsors
  • 6.
    Cardiovascular Diseases2 trials
    359 other sponsors
  • 7.
    Skin and Connective Tissue Diseases2 trials
    247 other sponsors
  • 8.
    Behavior and Behavior Mechanisms1 trial
    38 other sponsors
  • 9.
    Digestive System Diseases1 trial
    280 other sponsors
  • 10.
    Female Urogenital Diseases and Pregnancy Complications1 trial
    142 other sponsors
  • 11.
    Hemic and Lymphatic Diseases1 trial
    249 other sponsors
  • 12.
    Male Urogenital Diseases1 trial
    111 other sponsors
  • 13.
    Musculoskeletal Diseases1 trial
    238 other sponsors
  • 14.
    Nutritional and Metabolic Diseases1 trial
    211 other sponsors

Partnered Research Centres

1000 centres
location_city
assignment2
"Multiprofile Hospital for Active Treatment Dr. Hristo Stambolski" EOOD, Kazanlak
Address
16 "Starozagorska" Str., 6100 Kazanlak
Learn morearrow_forward
location_city
assignment1
"Multiprofile Hospital for Active Treatment Serdikamed" EOOD
Address
Base 2-district "Ovcha Kupel 2", 128 President Lincoln str., 1632 Sofia
Learn morearrow_forward
location_city
assignment2
424 General Military Training Hospital
Address
Gr. Lampraki 3, 54 636 Thessaloniki
Learn morearrow_forward
location_city
assignment39
A-Shine s.r.o.
Address
Sumavska 2, Vychodni Predmesti, 301 00 Pilsen
Learn morearrow_forward
location_city
assignment103
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
location_city
assignment335
Aalborg University Hospital
Address
Moelleparkvej 4, 9000 Aalborg
Learn morearrow_forward
Page 1 of 167

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Bristol-Myers Squibb Services Unlimited Company.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.